Acetylcholine Receptor Autoantibodies

What is the Acetylcholine Receptor Autoantibodies Test?

The Acetylcholine Receptor (AChR) Autoantibodies test measures antibodies that target acetylcholine receptors at the neuromuscular junction. These receptors are essential for transmitting nerve signals to muscles, enabling normal muscle contraction and strength.

In autoimmune conditions such as myasthenia gravis, the immune system produces antibodies that block or destroy acetylcholine receptors. This disrupts neuromuscular transmission, leading to muscle weakness that typically worsens with activity and improves with rest.

This blood test is a cornerstone investigation in neurology, helping confirm an autoimmune cause of muscle weakness and guiding further neurological assessment and management.

Why do I need a test for Acetylcholine Receptor Antibodies?

You may need this test if you experience fluctuating muscle weakness, especially affecting the eyes, face, throat or limbs. Myasthenia gravis often presents subtly at first, and symptoms may be mistaken for fatigue or stress-related weakness.

Testing is particularly important when weakness worsens with repeated use of muscles and improves after rest. Early identification allows timely treatment, which can significantly improve quality of life and prevent complications such as breathing or swallowing difficulties.

Symptoms and scenarios where testing is recommended:

• Drooping eyelids (ptosis)
• Double vision (diplopia)
• Difficulty chewing or swallowing
• Slurred or nasal speech
• Weakness in arms or legs
• Muscle fatigue that worsens during the day
• Difficulty holding the head up
• Shortness of breath in severe cases
• Suspected myasthenia gravis
• Monitoring known autoimmune neuromuscular disease

Benefits of the Acetylcholine Receptor Antibodies Test

• Key diagnostic marker for myasthenia gravis
  A positive result strongly supports an autoimmune neuromuscular diagnosis.
• Explains fluctuating muscle weakness
  Helps distinguish neurological autoimmune disease from muscular or metabolic causes.
• Supports early diagnosis and treatment
  Early detection allows prompt initiation of therapy to control symptoms.
• Guides neurological referral and imaging
  Positive results may prompt chest imaging to assess the thymus gland.
• Differentiates autoimmune from non-autoimmune weakness
  Helps avoid misdiagnosis and unnecessary investigations.
• Useful for disease classification
  Antibody levels can help differentiate generalised from ocular myasthenia.
• Supports long-term disease monitoring
  Antibody levels may be followed alongside clinical response.
• Simple and non-invasive diagnostic tool
  Requires only a standard blood sample.

Step-by-Step: How Testing Works

Choose your preferred testing method

You can attend one of our UK partner clinics or arrange a home or hotel visit with a mobile phlebotomist.

Option 1 – In-Clinic Blood Draw

1. Select your nearest UK clinic and book an appointment.
2. A clinician or phlebotomist collects a venous blood sample.
3. The sample is analysed for acetylcholine receptor antibodies.
4. Results are delivered securely online.

Option 2 – Home or Hotel Phlebotomy (+£60)

1. Book a UK-wide home or hotel visit at a convenient time.
2. A trained phlebotomist collects your blood sample on-site.
3. The sample is packaged and transported to the laboratory.
4. Results are uploaded digitally without the need to travel.

Access your report

You can download and share your results with your GP or neurologist for further interpretation.

Your Results Explained

Low / Negative Levels

A negative result means no detectable acetylcholine receptor antibodies.
This reduces the likelihood of myasthenia gravis but does not completely exclude it, as some patients have antibody-negative disease.

Normal / Expected Range

An expected result indicates no abnormal immune activity against acetylcholine receptors.
If symptoms persist, additional tests such as MuSK antibodies or nerve studies may be considered.

High / Positive Levels

A positive result indicates autoimmune targeting of acetylcholine receptors.
This strongly supports a diagnosis of myasthenia gravis and explains neuromuscular weakness.
Higher antibody levels often correlate with generalised disease rather than isolated eye involvement.